Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Fine

Laguna Beach, CA Medical Doctor

NPI 1346670007 CMS profile 242368

736 Kendall Dr, Laguna Beach, CA 92651

Open in the dashboard

General payments

$360,381

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Fine of Laguna Beach, CA is reported in the CMS Open Payments database as having received $360,381 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,105 15
2024 General $42,655 27
2023 General $33,007 19
2022 General $70,841 46
2021 General $67,317 37
2020 General $31,361 15
2019 General $85,096 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Fine
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Michael Fine were reported at $30,105. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Michael Fine California median Middle half National median
2019 $85,096 $161 $50–$652 $163
2020 $31,361 $114 $34–$392 $114
2021 $67,317 $137 $41–$509 $132
2022 $70,841 $152 $48–$573 $149
2023 $33,007 $162 $50–$581 $160
2024 $42,655 $162 $52–$583 $164
2025 $30,105 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $45,542 43 payments
  2. Genzyme Corporation $30,942 13 payments
  3. GlaxoSmithKline, LLC. $23,668 10 payments
  4. Pfizer Inc. $18,065 13 payments
  5. Vertex Pharmaceuticals Incorporated $14,880 11 payments
  6. Amgen Inc. $13,100 6 payments
  7. Otsuka America Pharmaceutical, Inc. $10,700 3 payments
  8. Sanofi Pasteur Inc. $10,568 6 payments
  9. Pacira Pharmaceuticals Incorporated $10,488 3 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $10,433 11 payments
  11. Other $171,995 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $290,583 139 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,128 15 payments
  3. Honoraria $21,880 10 payments
  4. Travel and Lodging $20,430 50 payments
  5. Food and Beverage $2,293 50 payments
  6. Education $66 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $41,092 40 payments
  2. DUPIXENT Immunology $10,500 2 payments
  3. Exparel $10,488 3 payments
  4. Zilretta $10,488 3 payments
  5. REXULTI $7,100 2 payments
  6. DASOTRALINE $6,418 8 payments
  7. SEP-856 $6,418 8 payments
  8. Afinion 2 $5,698 2 payments
  9. Yescarta $5,140 2 payments
  10. XARELTO $4,812 7 payments
  11. Other $98,771 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record